• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Poland·Industrials·NVA.WA
Share

P.A. Nova S.A. Stocks

PLN 18.5Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Strong

Risk

Considerable

Recommendation

Hold

Market Cap

PLN 50.26M

PLN 18.5
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1987 and headquartered in Gliwice, Poland, P.A. Nova S.A. is a prominent Polish construction company. The firm acts as a general contractor, delivering a wide array of construction services for commercial properties. Its diverse project portfolio includes retail chains, industrial halls, warehouses, petrol stations, shopping and commercial centers, public transport hubs like bus and train stations, schools, sports facilities, residential houses, and road infrastructure. Beyond construction, P.A. Nova S.A. offers comprehensive design services. This encompasses architectural design for commercial, industrial, social utility, and multi-family housing, alongside renovation designs for post-industrial sites and buildings listed as cultural heritage. Their design expertise also extends to interior design, visual information elements, public area planning, lighting for buildings and public spaces, and graphic designs with visualizations. The company further provides planning services, including studies of spatial planning conditions, local spatial planning, specialized planning designs, and urban and architectural concepts. In addition, P.A. Nova S.A. engages in property development and management. Distinctively, it also develops CAD/CFD/PDM software and provides specialized solutions for the water and sewage industry.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of NVA.WA is 22.8 and suggests 23.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026